Cannabis Use Disorder Clinical Trial
Official title:
A Phase 2B, 8-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults With DSM5 Current Cannabis Use Disorder (CUD)
A Phase 2B, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults with DSM-5 Current Cannabis Use Disorder (CUD)
The efficacy, safety and tolerability of the FAAH Inhibitor PF-0447845 in reducing cannabis use will be studied in a 4-site randomized, double-blind, placebo-controlled, parallel-group, outpatient clinical trial comparing PF-04457845 (4mg) and placebo in DSM-5 CUD individuals. Participants will be randomized in a 1:1 ratio to either PF-04457845 or placebo using random block sizes of 2 and 4, stratified by site and degree of cannabis use. Participants will receive motivational interviewing for 2 weeks before being randomized to receive study medication to make a quit attempt within the first week of treatment. Participants will receive active or placebo PF-04457845 for 8 weeks during which time they will be evaluated weekly in face to face visits. In addition, daily assessment of adherence to study medication and cannabinoid use will be conducted daily by cellphone. Measures of cannabinoid exposure (self-reported and urine toxicology), and problems related to the use of cannabis, will be assessed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
| Not yet recruiting |
NCT04139668 -
Vivitrol Treatment for Cannabis Use Disorder
|
Phase 2 | |
| Completed |
NCT01656707 -
Adaptive Treatment for Adolescent Cannabis Use Disorders
|
N/A | |
| Completed |
NCT03204305 -
Brain Imaging of Cannabinoid Receptors
|
Early Phase 1 | |
| Completed |
NCT05005013 -
A Teleheath tDCS Approach to Decrease Cannabis Use
|
N/A | |
| Recruiting |
NCT05292547 -
Repetitive Transcranial Magnetic Stimulation to People With Cannabis Use Disorder (SToP-C-rTMS x CUD)
|
N/A | |
| Completed |
NCT02932215 -
Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder
|
Phase 1 | |
| Completed |
NCT03430050 -
Progesterone for Cannabis Withdrawal
|
Early Phase 1 | |
| Withdrawn |
NCT03629106 -
Effects of Cannabis Abstinence on Symptomology and Cognition in Bipolar Disorder
|
N/A | |
| Completed |
NCT03334721 -
Gabapentin for Bipolar & Cannabis Use Disorders
|
Phase 2 | |
| Recruiting |
NCT04721353 -
Reducing Cannabis Overuse With Prazosin
|
Phase 4 | |
| Completed |
NCT03718520 -
The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
|
||
| Completed |
NCT03624933 -
Effects of Cannabis Abstinence on Symptoms and Cognition in Depression
|
N/A | |
| Recruiting |
NCT05836207 -
Rewards for Cannabis Abstinence-study
|
N/A | |
| Not yet recruiting |
NCT06114212 -
Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder
|
N/A | |
| Recruiting |
NCT05855668 -
Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment
|
N/A | |
| Recruiting |
NCT04517474 -
Comparing the Spanish Version of CANreduce With or Without Psychological Support and Treatment as Usual, Reducing Cannabis Use.
|
N/A | |
| Recruiting |
NCT05885542 -
SCORE Emerging Adult Cannabis Use & Stress
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06085222 -
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
|
Phase 1 | |
| Completed |
NCT03056482 -
Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)
|
Phase 4 |